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SUMMARY
Increased translocation of intestinal bacteria is a hallmark of chronic liver disease and contributes
to hepatic inflammation and fibrosis. Here we tested the hypothesis that the intestinal microbiota
and Toll-like receptors (TLRs) promote hepatocellular carcinoma (HCC), a long-term
consequence of chronic liver injury, inflammation and fibrosis. Hepatocarcinogenesis in
chronically injured livers depended on the intestinal microbiota, and TLR4 activation in non-bone
marrow-derived resident liver cells. TLR4 and the intestinal microbiota were not required for HCC
initiation but for HCC promotion, mediating increased proliferation, expression of the
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hepatomitogen epiregulin, and prevention of apoptosis. Gut sterilization restricted to late stages of
hepatocarcinogenesis reduced HCC suggesting that the intestinal microbiota and TLR4 represent
therapeutic targets for HCC prevention in advanced liver disease.
INTRODUCTION
Increased translocation of intestinal bacteria is common in patients with chronic liver
disease, and causes characteristic infectious complications in advanced disease stages
(Cirera et al., 2001; Schuppan and Afdhal, 2008; Tandon and Garcia-Tsao, 2008). In
addition, translocation of bacterial components termed pathogen-associated molecular
patterns (PAMPs) triggers inflammatory responses through Toll-like receptors (TLRs) in
both early and late disease stages (Dolganiuc et al., 2007; Fukui et al., 1991; Nolan and
Leibowitz, 1978; Seki et al., 2007; Wiest and Garcia-Tsao, 2005). Moreover, PAMPs from
the intestinal microbiota and TLR4 contribute to liver fibrosis and cirrhosis (Broitman et al.,
1964; Rutenburg et al., 1957; Seki et al., 2007). Notably, 80% of HCCs develop in fibrotic
or cirrhotic livers as a consequence of chronic liver injury (Fattovich et al., 2004; Luedde
and Schwabe, 2011) with HCC being the leading cause of death in patients with
compensated liver cirrhosis (Fattovich et al., 2004). However, pathways that are responsible
for the high rate of HCC development in the chronically injured and fibrotic liver remain
largely unknown. Here, we hypothesize that inflammatory and fibrogenic responses induced
by the gut microbiota and TLRs contribute to hepatocarcinogenesis, and might represent
targets for HCC prevention or treatment.
RESULTS
TLR4 is required for hepatocarcinogenesis in the chronically injured liver
To determine whether the known contribution of TLRs to hepatic inflammation and fibrosis
may set the stage for HCC development, we subjected C3H/HeJ and C3H/HeOuJ mice,
which carry respectively a non-functional and the wild type Tlr4, to a combination of
diethylnitrosamine (DEN) and the hepatotoxin carbon tetrachloride (CCl4). This model
incorporates chronic injury, inflammation, fibrogenesis and CCl4-mediated increases of
endotoxin levels (Seki et al., 2007), and thus shares several features with the
microenvironment in which the majority of human HCCs arise. Tumors developing by this
regimen showed typical features of HCC and microarray analysis revealed a characteristic
HCC expression profile with Afp, Gpc3 and Cdkn2b among the most upregulated genes with
greater than 90-fold increase in comparison to normal liver (data not shown). TLR4-wild-
type (Tlr4WT) and TLR4-inactivated mutant (Tlr4mut) mice had a similar tumor incidence
(100% in Tlr4WT mice, 78% in Tlr4mut mice, p=0.2105), but Tlr4mut mice displayed an 80–
90% reduction of tumor number and size, and an almost normal liver-body weight ratio 10.5
months after the initial DEN injection (Figure 1A).
Taking advantage of the separate initiation and promotion stages in this model, we further
analyzed the contribution of TLR4 at these stages. Following DEN injection, we observed
no differences in the induction of inflammatory genes Il6 and Ccl2, and p53-dependent
genes Cdkn1a and Bax between Tlr4WT and Tlr4mut mice (Figure S1A). DEN-induced liver
injury, as determined by serum ALT and AST levels, was exacerbated in Tlr4mut mice
(Figure S1A). However, the increased liver injury is unlikely to cause decreased
hepatocarcinogenesis in Tlr4mut mice as liver injury after DEN is thought to promote
hepatocarcinogenesis by inducing regenerative responses (Maeda et al., 2005; Naugler et al.,
2007). Moreover, despite a small trend towards decreased HCC development, all Tlr4mut
mice subjected to a purely genotoxic hepatocarcinogenesis protocol developed numerous
large tumors (Fig.S1B). Thus, TLR4 status exerts no major effect on genotoxic tumor
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initiation apart from an increased susceptibility of Tlr4mut mice to liver injury. In contrast,
we observed a significant impact of TLR4 status on tumor promotion by CCl4 with
proliferation markers mKi67, Pcna, Ccnb1 and Ccnb2, hepatic fibrogenesis markers Col1a1
and Acta2 and inflammatory markers Il6, Il1b, Tnf and Ccl2 strongly reduced in Tlr4mut
mice, as evidenced by microarray (data not shown) and qPCR analysis, despite increased
liver injury (Figure 1B, Figure S1C–D). Similar differences were observed after DEN plus 4
CCl4 injections suggesting a lasting effect of absent TLR4 signaling (Figure S1D). While
CCl4 plus DEN-induced liver injury was increased in Tlr4mut mice 48h after the last CCl4
injection, it was similar to Tlr4WT at earlier time points (Figure S1E) suggesting that the
Tlr4mut mice have a defect in DEN plus CCl4-induced injury resolution and wound healing
rather than a higher susceptibility to the initial injury. As chronic regeneration contributes to
replication-induced mutagenesis and HCC, we confirmed the reduction of proliferation
using Tlr4 knockout (Tlr4KO) mice in C57Bl/6 background and Ki-67
immunohistochemistry (Figure S1F–G).
To exclude that our findings reflect a particular role for TLR4 in the response to CCl4, we
tested two additional models in which DEN was combined with thioacetamide or a choline-
deficient diet, and found essentially the same results with decreased proliferation and
fibrogenesis (Figure S1H–J). We also tested whether TLR2, which recognizes PAMPs from
the gram-positive bacterial microbiota, contributes to hepatocarcinogenesis. However, we
did not find a role for TLR2 in DEN plus CCl4-induced proliferation or HCC development
(Figure S1K–L).
The intestinal microbiota and LPS promote hepatocarcinogenesis
Next, we examined whether ligands from the bacterial intestinal microbiota are triggers for
the observed TLR4-dependent tumor promotion. For this purpose, we gut-sterilized mice
with a well-established cocktail of oral antibiotics that eliminates commensal bacteria
(Rakoff-Nahoum et al., 2004) and reduces systemic LPS levels (Seki et al., 2007). This
treatment not only resulted in >99.5% reduction of 16s levels in the cecum (Figure S2A) and
an enlargement of the cecum commonly observed in germ-free mice (Figure 2A), but also a
highly significant reduction of tumor number, size and the liver-body weight ratio in our
DEN plus CCl4 HCC model (Figure 2A). Similar to data in the Tlr4mut mice, tumor
incidence was not affected by gut sterilization (100% in gut-sterilized vs 100% in control
mice). In addition to the similar degree of HCC reduction, gut-sterilization markedly pheno-
copied events observed in the Tlr4mut mice such as reduced expression of cell cycle, fibrosis
and inflammatory genes and increased liver injury (Figure 2B, Figure S2B). Accordingly,
the great majority of 1752 genes, that were significantly up- or downregulated by DEN plus
CCl4 and significantly up- or downregulated by TLR4 inactivation, were concordantly
regulated in DEN plus CCl4-treated liver from gut-sterilized mice (r=0.794, p<0.0001)
suggesting that TLR4 inactivation and gut sterilization exert highly similar biological effects
on the liver during hepatocarcinogenesis (Figure 2C). Like Tlr4mut mice, gut-sterilized mice
also did not show differences in inflammatory and p53-dependent gene expression in
response to acute DEN treatment but displayed increased liver injury (Figure S2C).
As a third approach in addition to TLR4 inactivation and gut sterilization, we treated mice
with a low, non-toxic dose of LPS via subcutaneous osmotic pumps for 12 weeks during
DEN plus CCl4-induced hepatocarcinogenesis. This low-dose LPS treatment led to a
significant increase in inflammatory gene expression, tumor number, tumor size and liver-
body weight ratio (Figure 3A, Figure S3) further confirming our hypothesis that the LPS-
TLR4 pathway promotes hepatocarcinogenesis. As Tlr5-deficient mice have an altered gut
microbiome (Vijay-Kumar et al., 2010), it is conceivable that TLR4 might also affect the
composition of the gut microbiome and thereby influence HCC development rather than
exerting direct effects in the liver. To address this possibility, we first performed 16s-based
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pyrosequencing of the cecal gut microbiota of wild-type and Tlr4mut mice as well as mice
treated with PBS or LPS. Unifrac analysis revealed no significant differences between
Tlr4WT and Tlr4mut mice, and between PBS- and LPS-treated mice, but showed distinct
clustering of the gut-sterilized mice (Figure 3B). Interestingly, differences between these 2
independent experiments were larger in the Unifrac analysis than differences between
Tlr4WT and Tlr4mut mice, or PBS- and LPS-treated mice again underlining that LPS and
TLR4 status exert no significant influence on the composition of the gut microbiome.
Moreover, the taxonomic distribution of the cecal gut microbiome was similar between
Tlr4WT and Tlr4mut mice, and PBS- and LPS-treated mice (Figure 3C) and among the 118
detected taxa at the genus level, we found no significant differences between Tlr4WT and
Tlr4mut mice, and only one taxon (firmicutes;bacilli;other;other;other) with a significant but
modest difference between PBS-treated mice (8.1% abundance) and LPS-treated mice (4.7%
abundance). However, as there was no difference in this taxon between Tlr4WT and Tlr4mut
mice, it is extremely unlikely that the different abundance of this taxon is responsible for
differences in hepatocarcinogenesis.
As a fourth approach, we investigated DEN plus CCl4-induced hepatocarcinogenesis in
germ-free (GF) and littermate controls that had been transferred to a specific-pathogen free
(SPF) environment after the initial DEN injection. GF mice displayed the typical
enlargement of the cecum, and had a significantly reduced tumor number, tumor size and
liver-body weight ratio in comparison to SPF mice (Figure 4A–B) thus confirming results in
mice gut-sterilized by antibiotics, and excluding that effects of antibiotics on the liver were
responsible for HCC reduction.
Non-bone marrow-derived resident hepatic cells mediate the tumor-promoting effect of
TLR4
To determine the hepatic cell that promotes HCC in response to TLR4 activation, we
generated TLR4-chimeric mice using a combination of irradiation, bone marrow
transplantation (BMT) and liposomal clodronate-mediated macrophage depletion (Seki et
al., 2009; Seki et al., 2007). This protocol achieved >97% suppression of LPS responses
after transplantation of Tlr4mut bone marrow (BM) into Tlr4WT mice, almost complete
restoration of LPS responses after transplantation of Tlr4WT BM into Tlr4mut mice and
substitution of F4/80-positive hepatic macrophages (Figure S4A). DEN plus CCl4-induced
hepatocarcinogenesis in TLR4-chimeric mice revealed no significant reduction of HCC
number, size and liver-body weight ratio in mice transplanted with Tlr4mut BM, whereas
TLR4 inactivation in resident (defined hereby as non-bone marrow-derived) liver cells
significantly reduced HCC number, size and liver-body weight ratio (Figure 5A). Similarly,
the induction of mKi67 and Pcna mRNA in response to acute DEN plus CCl4 treatment was
significantly reduced in Tlr4mut mice with Tlr4WT BM in comparison to Tlr4WT mice with
Tlr4WT BM (Figure 5B). Moreover, the depletion of hepatic macrophages by liposomal
clodronate did not affect the response to DEN plus CCl4 as evident by mKi67 and Pcna
mRNA levels (Figure S4B). To determine the resident liver cell that was responsive to LPS,
a sublethal dose of LPS was injected into healthy mice and mice that had undergone DEN
plus 8 CCl4 treatments, followed by determination of NF-κB p65 translocation. To avoid the
known rapid release of TNF and subsequent TNF-mediated NF-κB activation as a
cofounding factor, we employed either (i) TLR4-chimeric mice with Tlr4mut BM, (ii)
macrophage-depleted mice or (iii) mice deficient for both TNFR1 and IL-1R1 for this
experiment. In uninjured liver, we observed strong NF-κB p65 nuclear translocation in
desmin-positive hepatic stellate cells and Kupffer cells but no translocation in hepatocytes
after LPS injection (Figure S4C). In mice that had undergone DEN plus CCl4 treatment, we
confirmed p65 nuclear translocation in hepatic stellate cells but also observed p65
translocation in a large percentage of hepatocytes (Figure 5C, Figure S4D) suggesting that
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both hepatocytes and hepatic stellate are candidates for TLR4-dependent tumor promotion in
the chronically injured liver.
Epiregulin is a TLR4-regulated hepatomitogen that promotes hepatocarcinogenesis
Microarray analysis demonstrated cell cycle-related genes as most significantly affected by
TLR4 status or gut sterilization (Figure 2C). Our microarray and subsequent qPCR analysis
revealed reduced expression of two hepatomitogens, HGF and epiregulin (Toyoda et al.,
1995), in livers from DEN plus CCl4-treated Tlr4mut and gut-sterilized mice as well as from
TLR4-chimeric mice with Tlr4mut in resident liver and Tlr4WT BM (Figure 6A–C). Both
HGF mRNA (data not shown) and epiregulin mRNA were expressed much higher in hepatic
stellate cells than in whole liver, hepatocytes or hepatic macrophages (Figure 6D). As the
role of HGF in hepatocarcinogenesis remains controversial (Sakata et al., 1996; Santoni-
Rugiu et al., 1996; Takami et al., 2007), we focused our attention on epiregulin. Hepatic
stellate cells isolated from fibrotic livers secreted significantly more epiregulin than
quiescent hepatic stellate cells (Figure 6D), and stimulation of hepatic stellate cells with LPS
significantly upregulated epiregulin mRNA and protein in an NF-κB dependent manner
(Figure 6E). Moreover, LPS injection into mice either as a bolus or via the above described
chronic subcutaneous infusion also significantly increased epiregulin expression in the liver
(Figure 6D, Figure S3). Epiregulin mRNA expression was also induced by LPS in human
hepatic stellate cells and upregulated in livers of patients with alcoholic hepatitis, a group of
patients with typically very high LPS levels (Fukui et al., 1991) (Figure 6F).
To elucidate the contribution of epiregulin to hepatocarcinogenesis, we subjected wild-type
and epiregulin-deficient (EregKO) mice to DEN plus CCl4-mediated hepatocarcinogenesis.
Due to the much lower propensity of C57Bl/6 mice to develop HCC, we used an altered
protocol in which mice were subjected to DEN at day 15 postpartum followed by multiple
CCl4 injections. EregKO mice displayed a significant reduction of tumor number, size and
the liver-body weight ratio, albeit to a much lesser degree than Tlr4mut mice (Figure 6G).
Moreover, epiregulin was not upregulated at late stages in our hepatocarcinogenesis model
and did not differ between wild-type, Tlr4mut and gut-sterilized mice at these stages of
hepatocarcinogenesis (Figure 6H). Thus, additional factors must be responsible for the
striking reduction of hepatocarcinogenesis in Tlr4mut and gut-sterilized mice.
The intestinal microbiota and TLR4 suppress apoptosis in late stage of
hepatocarcinogenesis
Next we attempted to establish the time frame during which bacterial PAMPs exert the most
profound effects on hepatocarcinogenesis. Surprisingly, gut sterilization during the first 4.5
months of hepatocarcinogenesis showed only a moderate decrease of hepatocarcinogenesis
(Figure 7A). In contrast, gut sterilization during the last 4 months of hepatocarcinogenesis
reduced tumor number and size by 90% and 70%, respectively, and almost normalized the
liver-body weight ratio (Figure 7A). At this point, mice had not yet developed
macroscopically or microscopically visible tumors (Figure 7B) suggesting that gut
sterilization prevented tumor development rather than leading to the regression of already
established tumors. We additionally tested whether more selective gut decontamination with
rifaximin, a widely used non-absorbable antibiotic for the prevention of hepatic
encephalopathy in patients with end-stage liver disease (Bass et al., 2010), could influence
hepatocarcinogenesis at late stages. We observed a borderline significant reduction of tumor
numbers but saw no significant reduction in tumor size (data not shown) suggesting only
moderate efficacy of rifaximin monotherapy on hepatocarcinogenesis at late stages (Figure
S5).
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To determine whether gut-sterilization might affect already established tumors, we treated
WT mice at a time point where tumors were already present with the quadruple antibiotics
cocktail for 6 weeks. However, we found no significant change of tumor size, number or
liver-body weight ratio in comparison to control mice (Figure 7C). When following single
tumors by weekly ultrasound monitoring, we also saw no change in tumor size in
antibiotics-treated mice (data not shown).
To further determine the mechanism by which the intestinal microbiota and TLR4 promote
hepatocarcinogenesis, we analyzed gene expression, proliferation and apoptosis in gut-
sterilized and Tlr4mut mice. Due to the lower tumor number and size, the overall amount of
Ki-67 staining in Tlr4mut and gut-sterilized mice was expectedly lower (data not shown).
Microarray comparison showed a highly similar gene expression pattern in HCC from wild-
type, Tlr4mut and gut-sterilized mice (Figure S6A), and HCCs from these groups did not
cluster separately as shown by dendrogram and Unifrac analysis (Figure S6B–C). There was
a small but non-significant trend towards lower AFP and Ki-67 in HCCs from gut-sterilized
mice and Tlr4mut mice which was most likely due to the smaller size of the tumors in these
groups. There were no genes that showed significant changes, as defined by a corrected p-
value of p<0.05, in the Tlr4mut or gut-sterilized HCC group when compared to the Tlr4WT
HCC group (data not shown). Moreover, there were no differences in tumor grade (Figure
S6D), and there was a similar loss of collagen IV staining in HCCs from all groups (Figure
S6E).
Microarray analysis showed no differences in expression of the cancer stem cell marker
prominin 1/CD133 (data not shown), and we found only small and very rare clusters of cells
positive for the progenitor marker A6 (Engelhardt et al., 1990) with mostly low A6
expression and morphology of intermediate hepatobiliary cells (Figure S6F). Similarly, there
were only few cells with strong pan-cytokeratin signal typical for oval cells in tumors of all
treatment groups and a larger but highly variable amount of cells with weak pan-cytokeratin
expression typical of intermediate hepatobiliary cells in all groups (Figure S6G-H).
Altogether, the microarray and immunohistochemical data suggest that TLR4 signaling is
unlikely to promote hepatocarcinogenesis via progenitor cells. There was also no significant
difference in Ki-67 positive cells in non-tumor liver between these groups suggesting that
TLR4 and the intestinal microbiota do not promote tumor formation by increasing
proliferation in non-tumor liver (Figure 8A).
Both gut-sterilized and Tlr4mut mice displayed a significant increase in cleaved-caspase 3-
positive cells with predominant expression of cleaved-caspase 3 in hepatocytes in non-tumor
areas (Figure 8B). Notably, the number of cleaved caspase 3-positive cells was inversely and
highly significantly correlated with tumor number, size and the liver-body weight ratio
(Figure 8B) further underlining the biological relevance of these findings. Significant
increases in cleaved-caspase 3 positive cells and a strong and highly significant inverse
correlation between cleaved-caspase 3 and tumor number, size and liver-body weight ratio
were also observed in mice that were gut-sterilized at late time points (Figure 8CD).
Moreover, the expression of NF-κB-regulated anti-apoptotic genes Birc3, Birc5 and Nos2
(Hatano et al., 2001; Wang et al., 1998) was reduced in non-tumor areas of livers from
Tlr4mut and antibiotics-treated mice (Figure 8E) suggesting that TLR4 and the intestinal
microbiota provide survival signals that are advantageous for hepatocarcinogenesis.
DISCUSSION
Chronic inflammation is a key contributor to carcinogenesis in various organs including the
stomach, colon, lung and liver (Balkwill and Mantovani, 2001; Grivennikov et al., 2010). In
the liver, 80% of HCCs develop in a microenvironment characterized by chronic injury,
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inflammation and fibrosis. However, mediators that are responsible for the high risk to
develop HCC in the chronically injured liver are largely unknown. Translocation of bacteria
and bacterial PAMPs is common in chronic liver disease (Schuppan and Afdhal, 2008;
Tandon and Garcia-Tsao, 2008), and promotes inflammation and fibrosis in chronic liver
injury (Seki et al., 2007).
We now provide several lines of evidence that the intestinal microbiota and TLR4 link
inflammation and carcinogenesis in the chronically injured liver. Genetic TLR4 inactivation,
gut sterilization or germ-free status decrease HCC development by ≈80%. Conversely,
prolonged treatment with low-dose LPS significantly increases HCC development. These
findings are similar to intestinal tumorigenesis in which TLR4 and MyD88 drive
carcinogenesis (Fukata et al., 2007; Lee et al., 2010; Rakoff-Nahoum and Medzhitov, 2007).
In contrast to the intestine, the liver is not in direct contact with intestinal bacteria. However,
the liver is the first target of intestinal bacteria and PAMPs translocating into the portal
circulation. Moreover, translocation increases with the development of liver fibrosis and
cirrhosis (Fukui et al., 1991; Lin et al., 1995; Wiest and Garcia-Tsao, 2005). Our HCC data
in germ-free mice effectively exclude the possibility that the employed antibiotics with low
systemic bioavailability might have exerted direct effects on the liver in our model.
Moreover, 16s pyrosequencing demonstrated that TLR4 status and LPS treatment do not
significantly change the composition of the gut microbiome with the exception of one taxon
whose abundance differed between LPS- and PBS-treated mice but not between Tlr4WT and
Tlr4mut mice.
In contrast to a previous study (Yu et al., 2010), we find no significant contribution of the
intestinal microbiota and TLR4 to tumor initiation or purely genotoxic
hepatocarcinogenesis, but demonstrate two distinct mechanisms through which the intestinal
microbiota and TLR4 promote HCC: In early stages, TLR4-deficiency and gut sterilization
decrease hepatic proliferation and fibrogenesis. Accordingly, gut sterilization or LPS
infusion given during early stages moderately decrease or increase hepatocarcinogenesis,
respectively. Our study provides evidence that TLR4-dependent HCC promotion in the early
phases is predominantly mediated by TLR4-dependent secretion of growth factors such as
epiregulin by hepatic stellate cells. Thus, hepatic stellate cells might provide a link between
fibrosis and HCC development by increasing growth factors. Based on previous studies
showing promotion of growth factor signaling and tumor development by ECM-rich and
stiff environment (Levental et al., 2009; Samuel et al., 2011), it is likely that growth factors
and ECM produced by hepatic stellate cells synergize in tumor promotion. Our results are
consistent with recent studies showing TLR4- and MyD88/Trif-dependent regulation of
epiregulin and regeneration after injury in the intestine (Brandl et al., 2010; Hsu et al.,
2010). However, HCC reduction in epiregulin-deficient mice was less pronounced than in
Tlr4mut or gut-sterilized mice suggesting that additional mechanisms contribute to TLR4-
dependent HCC promotion.
The most significant contribution of the intestinal microbiota in our study occurred during
later stages of hepatocarcinogenesis independently of CCl4-induced upregulation of growth
factors and regenerative responses. These results are remarkably similar to a previous study
in which NF-κB inhibition at late but not early stages reduced inflammation-associated HCC
(Pikarsky et al., 2004). In line with this study, we detected decreased induction of NF-κB
regulated genes and an increased rate of apoptosis in all groups that were protected from
HCC development. Accordingly, we found that the hepatocyte compartment which had been
unresponsive to LPS in healthy livers became highly sensitive to LPS in DEN plus CCl4-
injured livers. The biological relevance of increased apoptosis for HCC development is
emphasized by the strong inverse correlation of tumor number, tumor size, and liver-body
weight ratio with cleaved-caspase 3-positive cells in two sets of gut-sterilized mice and in
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Tlr4mut mice. In addition to its role in Abcb4KO chronic liver injury model (Pikarsky et al.,
2004), hepatocellular NF-κB also acts a promoter of hepatocarcinogenesis in lymphotoxin-
driven HCC (Haybaeck et al., 2009) suggesting a requirement for hepatocellular NF-κB in
HCC occurring in the setting of significant inflammation. In contrast, hepatocellular
inactivation of NF-κB in genotoxic HCC models enhances hepatocarcinogenesis (He et al.,
2010; Maeda et al., 2005). Finally, the complete but rather unphysiological absence of NF-
κB activity by Nemo or TAK1 deletion causes chronic hepatocyte injury, liver cirrhosis and
spontaneous HCC (Bettermann et al., 2010; Inokuchi et al., 2010; Luedde et al., 2007).
Thus, the presence of inflammation and the degree of NF-κB inhibition appear to be crucial
factors that determine whether NF-κB promotes or inhibits hepatocarcinogenesis.
The majority of apoptosis in our study occurred in non-tumor areas of the liver suggesting
that pro-survival signals provided by the intestinal microbiota and TLR4 are required for the
survival of tumor precursors, and that apoptosis prevents the development of tumor lesions
rather than leading to regression of already established tumors. Accordingly, we observed no
effect of gut sterilization on already established HCCs. These results are consistent with
previous findings that gene expression profiles in non-tumor liver tissue, including gene sets
related to NF-κB, TNFα and interferon signaling - all downstream targets of TLR4 - are
crucial determinants of tumor recurrence whereas tumor profiles have no prognostic value
(Hoshida et al., 2008).
One important difference between our findings and many previous studies is the tumor-
promoting effect of inflammatory signals in resident liver cells. Bone marrow-derived cells
such as macrophages are abundant sources of inflammatory cytokines and contribute to
genotoxic HCC (Maeda et al., 2005). Our studies in chimeric mice demonstrate that BM-
derived cells including hepatic macrophages do not mediate the tumor-promoting effects of
TLR4 in both acute and long-term HCC models. Accordingly, we found that both hepatic
stellate cells and hepatocytes are targets of LPS in the liver with TLR4 on hepatic stellate
cells most likely mediating regenerative response after injury, and TLR4 on hepatocytes
preventing apoptosis of hepatocytes and premalignant cells. Oval cells represent another
potential target of LPS and LPS-induced mediators such as TNFα (Brooling et al., 2005),
but we found only few areas with A6- and cytokeratin-positive cells typical of oval cells in
our tumor model, and no influence of TLR4 status and gut-sterilization on the number these
cells. Further studies in mice with conditional TLR4 deletion are required to distinguish the
relative contribution of TLR4 expressed in hepatocytes versus TLR4 expressed in hepatic
stellate cells to hepatocarcinogenesis.
Together with results from a previous study (Pikarsky et al., 2004), our data suggest chronic
liver injury affects the resident liver compartment and makes resident liver cells and/or
tumor-forming cells more dependent on inflammatory signals for their survival. With the
majority of HCCs occurring in chronically injured livers but many mouse models lacking
chronic injury, it is possible that the contribution of inflammatory pathway to human HCC
has been underestimated. Our results differ from a previous study in which BM-derived cell
populations were suggested to promote HCC through TLR4 (Yu et al., 2010). Notably,
conclusions on the contribution of BM were based on acute responses to DEN instead of
HCC development in that study. Moreover, TLR4- and MyD88-dependent carcinogenesis in
the intestine and hepatic carcinogenesis in HCV transgenic mice are also promoted by
resident cells (Hsu et al., 2010; Lee et al., 2010; Machida et al., 2009; Rakoff-Nahoum and
Medzhitov, 2007). In the latter study, TLR4 promotes HCC in alcohol-treated HCV
transgenic mice through the upregulation of stem cell markers. Although we observed a
strong increase in the stem cell marker prominin 1/CD133 in HCCs, we observed no
influence of TLR4 status on its expression in our microarray analysis suggesting that there
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may be additional mechanisms by which TLR4 promotes hepatocarcinogenesis in alcohol-
treated HCV transgenic mice.
In order to enable bone marrow transplantation studies in adult mice, our study took
advantage of the high HCC susceptibility of the C3H strain and used Tlr4WT C3H/HeOuJ
and Tlr4mut C3H/HeJ mice. We can exclude that genetic differences besides TLR4 play a
role in the observed promotion of HCC by TLR4 and the intestinal microbiota based on the
following findings: (i) The Tlr4 locus is the only SNP among 2059 tested SNPs that differs
between C3H/HeOuJ and C3H/HeJ mice (www.jax.org/phenome). (ii) Findings in C3H/
HeOuJ and C3H/HeJ mice were confirmed in WT and Tlr4KO C57Bl/6 mice. (iii) A large
set of experiments solely performed in C3H/HeOuJ mice such as gut sterilization and LPS
infusion by osmotic pumps demonstrated the HCC-promoting role for the intestinal
microbiota and the TLR4 ligand LPS.
The presented data provide conclusive evidence that the intestinal microbiota exerts a
profound influence on HCC promotion in the chronically injured liver. Moreover, our study
provides a strong rationale for targeting the intestinal microbiota and TLR4 for the primary
or secondary prevention of HCC. The astounding reduction of HCC by gut sterilization at
late stages suggests that these treatments might exert protective effects even in advanced
liver disease. HCC has become the major cause of death in patients with compensated liver
cirrhosis and there is a need for more effective treatment and preventative strategies (Bruix
et al., 2004). To translate our findings into clinical medicine, clinically feasible methods of
targeting the intestinal microbiota or TLR4 need to be established. The quadruple
combination of antibiotics employed in the current study almost completely decontaminated
the intestine and prevented 80% of murine HCCs, but is not suitable for long-term treatment
due to known side effects in patients with advanced liver disease. Our study suggests that
rifaximin, a nonabsorbable antibiotic that is widely used in patients with advanced liver
disease (Bass et al., 2010), may moderately reduce HCC development. Further studies are
required to determine if longer treatment duration or combination with other well-tolerated
antibiotics could improve the effects of rifaximin, or if other approaches such as TLR4
antagonists would reduce HCC development.
EXPERIMENTAL PROCEDURES
Mice, HCC induction and evaluation
C3H/HeOuJ, C3H/HeJ, TLR2-deficient mice, TLR4-deficient mice (C57Bl6/10ScN),
TNFR1-/IL-1R1-double deficient and C57Bl/6 mice were purchased from Jackson
laboratories. Ereg-deficient mice in a C57Bl/6 background were obtained from the Mouse
Mutant Regional Resource Center at the University of North Carolina.
In C3H/HeOuJ and C3H/HeJ mice, HCC was induced by intraperitoneal injection of DEN
(100 mg/kg) at ages 6–14 weeks followed by 6–12 biweekly injections of carbon
tetrachloride (0.5 ml/kg i.p., dissolved in corn oil) unless stated otherwise. For Ereg-
deficient mice and C57Bl/6 wild-type controls, HCC was induced by the combination of
DEN (25 mg/kg i.p.) given at day 15 postpartum, and 22 weekly injections of CCl4 (0.5 ml/
kg i.p., dissolved in corn oil). For Tlr2KO mice and C57Bl/6 wild-type controls, HCC was
induced by the combination of DEN (100 mg/kg, i.p.) given at the age of 8 weeks, followed
by 25 biweekly injections of CCl4 (0.5 ml/kg, i.p., dissolved in corn oil). Gut-sterilization
was done as previously described (Rakoff-Nahoum et al., 2004; Seki et al., 2007) using a
combination of ampicillin (1 g/l), neomycin (1 g/l), metronidazole (1 g/l) and vancomycin
(500 mg/l) in drinking water. For rifaximin studies, mice either received 250 mg/l rifaximin
in drinking water with rifaximin dissolved in Ora-Plus/Ora-Sweet (Cober et al., 2010) or
Ora-Plus/Ora-Sweet vehicle translating to a rifaximin dose of 50 mg/kg/d. Germ-free (GF)
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mouse experiments were performed at the University of North Carolina National
Gnotobiotic Rodent Resource Center, Chapel Hill, North Carolina. All mice received DEN
(25 mg/kg i.p.) in the germ-free status at day 15 postpartum. One week after DEN, 50% of
mice were moved to a specific pathogen free (SPF) environment. 4 weeks after the DEN
injection, GF and SPF mice received a total of 10 CCl4 injections (1 injection per week, at
0.5 ml/kg i.p. in corn oil). Germ-free status was confirmed by bi-weekly monitoring for the
presence of bacteria in the feces by aerobic and anaerobic culture as well as Gram staining
of the stool. Mice were sacrificed 30 weeks after the initial DEN injection.
Evaluation of tumor number and size was determined as described by counting the number
of visible tumors and measuring the size of the largest tumor with a caliper (Naugler et al.,
2007). After sacrifice, livers were explanted, digitally photographed and weighed to
calculate the liver-body weight ratio. To evaluate acute effects of TLR4 and the intestinal
microbiota, adult mice were treated with DEN (100 mg/kg i.p.) alone or in combination with
either two or four injections of CCl4 (0.5 ml/kg i.p.), two injections of thioacetamide (400
mg/kg i.p.) or 4 weeks of a choline-deficient L-amino-acid-defined diet. For some
experiments, mice were treated with lipsomomal clodronate or liposome vehicles (200 µl
i.p.). For some experiments, liver fibrosis was induced by ligating the common bile duct as
previously described (Kluwe et al., 2010; Seki et al., 2007). All animal procedures were in
accordance to guidelines by the National Institutes of Health, and approved by the
Institutional Animal Care and Use Committee at Columbia University and the Institutional
Animal Care and Use Committee at the University of North Carolina, Chapel Hill.
Human samples and cells
Patients with clinical, analytical and histological features of alcoholic hepatitis were
prospectively obtained in the Liver Unit of the Hospital Clínic, Barcelona, between January
2009 and December 2010 (n=10). Liver biopsies were obtained using a transjugular
approach. In all patients, liver specimens were analyzed by an expert liver pathologist.
Fragments of normal livers were obtained from optimal cadaveric liver donors (n=2) or
resection of liver metastases (n=2). All controls had normal serum aminotransferase levels
and normal liver histology. Human hepatic stellate cells were isolated by density gradient-
based centrifugation from normal liver as described (Kluwe et al., 2010) and used between
passage 3 and 5. Procedures involving human materials were approved by the
Investigational Review Board of the Hospital Clínic of Barcelona, and informed consent was
obtained from all subjects.
Primary cell isolations
Primary hepatic stellate cells, Kupffer cells and hepatocytes were isolated from either
normal or DEN plus 2×CCl4-treated mice using retrograde liver perfusion and isolation
techniques as previously described (Seki et al., 2007). For some experiments, hepatic stellate
cells were infected with an adenovirus expressing IκB superrepressor (AdIκBsr) or an empty
control adenovirus as described before (Seki et al., 2007).
SIGNIFICANCE
Hepatocellular carcinoma (HCC) typically develops in chronically injured livers, but
mediators that promote HCC in this setting are not well characterized. Our study
demonstrates that TLR4 activation by LPS from the intestinal microbiota contributes to
injury- and inflammation-driven tumor promotion, but not to tumor initiation. Different
from most previous studies that focused on inflammatory pathways in bone marrow-
derived cells, our study finds that the LPS-TLR4 pathway promotes HCC by increasing
proliferative and anti-apoptotic signals in non-bone marrow-derived resident liver cells.
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Our finding that gut sterilization efficiently prevents HCC even at very late stages may
provide a basis for clinically applicable HCC prevention strategies in patients with
chronic liver injury.
Highlights
• The gut microbiota and TLR4 play a role in HCC promotion but not in HCC
initiation.
• Gut sterilization, germ-free status or TLR4 inactivation reduce HCC by 80–
90%.
• Gut sterilization efficiently suppresses hepatocarcinogenesis even when given
late.
• Resident liver cells but not BM-derived cells promote HCC through TLR4.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. TLR4 contributes to hepatocarcinogenesis
A. Tlr4WT mice (n=10) and Tlr4mut (n=9) were injected with DEN (100 mg/kg i.p.) at the
age of 12 weeks followed by 6 injections of CCl4 (0.5 ml/kg i.p.) and sacrificed 10.5 months
after DEN. Shown are tumor number, largest tumor size, liver-body weight ratio, H&E
sections and representative images. B. Tlr4WT (n=14) and Tlr4mut mice (n=15) were treated
with DEN followed by 2 injections of CCl4. Gene expression and ALT and AST levels were
determined 48h after the second CCl4 injection. Fold induction in comparison to untreated
livers. Data are represented as means ± SD. * p<0.05, ** p<0.01. See also Figure S1.
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Figure 2. The intestinal microbiota promotes hepatocarcinogenesis
A. WT mice (C3H/HeOuJ) were treated with DEN plus 6 injections of CCl4 and either did
(n=11) or did not (n=7) receive antibiotics (ampicillin, neomycin, metronidazole,
vancomycin) in their drinking water starting 2 weeks before and throughout the entire
period. Shown are representative images of ceca, tumors and H&E sections. B. WT mice
were treated with DEN plus 2 injections of CCl4, and either did (“Abx”, n=14) or did not
(“Ctrl”, n=9) receive the above-described antibiotics cocktail 2 weeks before DEN injection
until they were sacrificed 48h after the last CCl4 injection. Gene expression is expressed as
fold induction in comparison to untreated liver. Liver injury was assessed by ALT and AST
measurements C. Tlr4WT, Tlr4mut and Tlr4WT mice treated with antibiotics were injected
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with DEN and two subsequent injections of CCl4 and sacrificed 48h later. RNA of livers
from untreated Tlr4WT mice (n=3), DEN plus CCl4-treated Tlr4WT (n=4), DEN plus CCl4-
treated Tlr4mut mice (n=4) and antibiotics plus DEN plus CCl4-treated Tlr4WT mice (n=4)
were used for microarray analysis. The left heatmap shows changes of 1752 genes in the
Tlr4mut and antibiotics-treated mice that were (i) at least 1.8-fold up- or downregulated by
DEN plus CCl4 treatment in Tlr4WT mice in comparison to untreated mice, and (ii) 1.8-fold
up- or downregulated in DEN plus CCl4-treated Tlr4mut mice in comparison to DEN plus
CCl4-treated Tlr4WT mice. The right heatmap shows genes fulfilling the same conditions as
described above restricted to the GO categories 0007049, 0009611 and 0005578. Data are
represented as means ± SD. * p<0.05, ** p<0.01. See also Figure S2.
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Figure 3. LPS promotes hepatocarcinogenesis but does not change the intestinal bacterial
microbiota
A. Tlr4WT (C3H/HeOuJ) mice were treated with DEN plus 6 injections of CCl4 and either
received LPS (300 µg/kg/d, n=9) or PBS (n=10) via subcutaneous pumps starting one week
before the first CCl4 injection for 12 weeks. Mice were sacrificed 8.5 months after DEN
injection to determine tumor number, size and liver-body weight ratio. * p<0.05, ** p<0.01.
B. Unifrac analysis of 16s sequencing results of the cecal microbiome in Tlr4WT (n=3) and
Tlr4mut (n=4) mice, Tlr4WT mice treated with subcutaneous PBS (n=4) or LPS (n=4) pumps
for 2 weeks, or Tlr4WT mice receiving antibiotics (n=4) for 2 weeks. C. Taxonomic
distribution of the cecal microbiome in Tlr4WT and Tlr4mut mice, Tlr4WT mice treated with
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subcutaneous PBS or LPS pumps for 2 weeks, or mice receiving antibiotics for 2 weeks. The
chart contains a total of 118 taxa at the genus level and the top 20 taxa are annotated on the
left with most abundant taxa listed on top. Data are represented as means ± SD. * p<0.05, **
p<0.01. See also Figure S3.
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Figure 4. Germ-free status decreases hepatocarcinogenesis
Germ-free (GF) C57Bl/6 mice were subjected to DEN (25 mg/kg i.p.) injection, split into
specific-pathogen free (SPF) and GF groups, and then received 10 CCl4 (0.5 ml/kg i.p.)
injections. A. Ceca of GF and SPF mice are shown on the far left and representative livers
with tumors are shown on the right. B. Tumor number, size and liver-body weight ratio was
determined in SPF mice (n=9) and GF mice (n=10). Data are represented as means ± SD. *
p<0.05, ** p<0.01.
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Figure 5. Resident liver cells mediate TLR4-dependent tumor promotion
A. Tlr4WT and Tlr4mut mice were subjected to BMT (n≥10 per group) at 8 weeks followed
by treatment with DEN plus 8 injections of CCl4. Mice were sacrificed 10.5 months after
DEN. Shown are representative images of tumors and H&E sections, as well as tumor
number, size and liver body weight ratio. B. Tlr4WT (n=7) and Tlr4mut mice (n=6) were
transplanted with wild-type bone marrow and treated with DEN plus 2 injections of CCl4 at
the age of 8 weeks. Proliferation markers were evaluated by qPCR and shown as fold
induction in comparison to untreated mice. C. TLR4 chimeric mice with Tlr4WT resident
cells and Tlr4mut BM (n=3) were treated with DEN plus CCl4 as described above. 10.5
months after DEN, LPS (10 mg/kg i.v.) was injected and NF-κB p65 nuclear translocation
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was determined by immunohistochemistry and confocal microscopy in non-tumor liver
areas. Hepatic stellate cells were visualized by desmin staining and nuclei were visualized
by Hoechst staining. Green and white arrows indicate NF-κB translocation in hepatic stellate
cells and hepatocytes respectively. The percentage of hepatic stellate cells (HSC) and
hepatocytes (Hep) with positive nuclear p65 was determined. Data are represented as means
± SD. * p<0.05, ** p<0.01. See also Figure S4.
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Figure 6. Epiregulin is an LPS-inducible promoter of hepatocarcinogenesis
A. Ereg and Hgf mRNA were determined in Tlr4mut mice (n=14), Tlr4mut (n=15) and
antibiotics-treated Tlr4WT (n=9) after DEN and 2×CCl4 injections. Fold induction vs.
untreated livers. B. Ereg and Hgf mRNA were determined in TLR4-chimeric mice with
Tlr4WT resident cells and Tlr4WT BM (n=6) or Tlr4mut resident cells and Tlr4WT BM (n=6)
after treatment with DEN and 2 CCl4 injections. Fold induction vs. untreated livers. C.
Western blot of HGF from Tlr4WT mice, Tlr4mut mice and antibiotics-treated mice after
DEN and 2×CCl4 injections. D. Hepatocytes (Hep), Kupffer cells (KC) and hepatic stellate
cells (HSC) were isolated from liver treated with DEN and 2 injections of CCl4 followed by
analysis of Ereg mRNA expression by qPCR (left panel). Shown is a fold-induction vs.
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whole liver. Ereg mRNA was isolated in liver extracts from CCl4-treated mice injected with
LPS (10 mg/kg i.v.) or PBS 4 days after the last CCl4 injection (second panel from left).
Activated hepatic stellate cells were isolated from CCl4-treated and bile duct-ligated livers.
Epiregulin was determined by ELISA 24hr after plating. E. Hepatic stellate cells from DEN
plus 2×CCl4 treated mice were stimulated with LPS (100 ng/ml) in the presence of either an
adenoviral IκB superrepressor (AdIκBsr) or empty shuttle virus (AdSh) by qPCR (left panel)
or ELISA (right panel) F. EREG expression was determined in normal liver (“NL”, n=4)
and livers of patients with alcoholic hepatitis (“AH”, n=10, left panel) and in activated
human hepatic stellate cells stimulated with LPS (100 ng/ml, right panel). G. WT (n=11)
and EregKO mice (n=14) were treated with DEN plus 22 injections of CCl4. Mice were
sacrificed 6.5 months after DEN. Shown are representative images of tumors as well as
tumor number, size of the largest tumor, and liver body weight ratio. H. Ereg expression
was analyzed in non-tumorous regions of DEN plus CCl4-treated Tlr4WT (n=12), Tlr4mut
mice (n=9) and antibiotics-treated Tlr4WT mice (n=6) 10.5 months after DEN. Fold
induction vs. untreated liver. Data are represented as means ± SD. * p<0.05, ** p<0.01. nd,
non-detectable
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Figure 7. The intestinal microbiota promotes HCC in late stages of hepatocarcinogenesis
A. WT mice (C3H/HeOuJ) were treated with DEN (100 mg/kg i.p. at the age of 6 weeks)
and 12 CCl4 (0.5 ml/kg i.p.) injections and were either not gut-sterilized (“N”, n=7), gut-
sterilized starting 2 weeks before DEN injection until 2 weeks after the last CCl4 injection
(“E”, n=10), or 2 weeks after the last CCl4 injection until they were sacrificed (“L”, n=8)
followed by determination of tumor number, size and liver-body weight ratio. B. WT mice
treated as described above were sacrificed at the time point when the gut-sterilization
treatment was started to determine whether macroscopic or microscopic tumors were
present. C. WT mice were treated with DEN (25 mg/kg i.p.) at day 15 postpartum followed
by 14 weekly injections of CCl4. After confirming the presence of tumor by ultrasound (data
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not shown), mice were treated with (“Abx”, n=7) or without (“Ctrl”, n=6) antibiotics
(ampicillin, vancomycin, neomycin and metronidazole) starting 2 weeks after the last CCl4
injection. After 6 weeks of antibiotics, mice were sacrificed and tumor number, size and
liver-body weight ratio was determined. Data are represented as means ± SD. * p<0.05, **
p<0.01. ns, non-significant. See also Figure S5.
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Figure 8. TLR4 and the intestinal microbiota protect from apoptosis
A–B. Livers from Tlr4WT (n=11), Tlr4mut (n=9) or antibiotics-treated Tlr4mut mice (n=7)
were stained for Ki-67 (A.) or cleaved-caspase 3 (B.) followed by quantification. Correlation
between the number of cleaved-caspase 3 positive cells and tumor number, size and liver-
body weight ratio was determined. C–D. Tlr4WT were either not gut-sterilized (n=7), or gut-
sterilized 2 weeks after the last CCl4 injection until they were sacrificed (n=8). Livers were
stained for Ki-67 and cleaved-caspase 3 followed by quantification (B). Correlation between
the number of cleaved-caspase 3 positive cells and tumor number, size and liver-body
weight ratio was determined (C). E. Nos2, Birc3 and Birc5 mRNA levels were compared
between livers from Tlr4WT (n=12) and Tlr4mut (n=9), and between untreated (n=9) and
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antibiotics treated (n=6) Tlr4WT. Data are represented as means ± SD. * p<0.05. See also
Figure S6.
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